Edwards Lifesciences Corporation

As of June 30, 2026, Edwards Lifesciences Corporation carries a market capitalization of 52.16B, placing it among publicly traded companies globally. Its enterprise value stands at 48.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Edwards Lifesciences Corporation's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Edwards Lifesciences Corporation has 576.60M shares outstanding.

As of June 30, 2026, Edwards Lifesciences Corporation trades at a trailing price-to-earnings ratio of 52.23. The price-to-sales ratio is 8.06, and the price-to-book ratio stands at 4.91.

As of June 30, 2026, Edwards Lifesciences Corporation trades at an EV/EBITDA multiple of 30.18 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 33.62 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Edwards Lifesciences Corporation trades at an EV/FCF ratio of 28.32, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 48.72B versus a market cap of 52.16B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Edwards Lifesciences Corporation maintains a current ratio of 4.52, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Edwards Lifesciences Corporation posted a return on equity (ROE) of 9.50, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.62 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.35, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.85, useful for judging operating efficiency across full business cycles. The company generates approximately 408,294.67 in revenue per employee across its workforce of 15,950.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.27 indicates how many times Edwards Lifesciences Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Edwards Lifesciences Corporation recorded 439.00M in income tax expense. That works out to an effective tax rate of 30.97, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.42B, leaving 1.00B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Edwards Lifesciences Corporation's stock has gained approximately 16.39% over the past 52 weeks. The 50-day moving average sits at 88.06, while the 200-day moving average is 85.23.

Over the twelve months ended June 30, 2026, Edwards Lifesciences Corporation generated 6.51B in revenue and converted that into 1.00B in net income, yielding earnings per share of 1.68. EBITDA reached 1.61B, while operating income came in at 1.83B.

As of June 30, 2026, Edwards Lifesciences Corporation holds 4.25B in cash and equivalents against 704.40M in total debt, resulting in a net debt position of -2.31B. Total book value stands at 10.62B, with working capital of 5.31B providing operational flexibility.

Edwards Lifesciences Corporation produced 1.72B in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled 1.72B - equivalent to 2.97 per share.

Over the twelve months ended June 30, 2026, Edwards Lifesciences Corporation posted a gross margin of 77.84, reflecting its pricing power and cost economics. The operating margin of 28.09 and net profit margin of 15.43 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.27, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.31, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Edwards Lifesciences Corporation shareholders.

Edwards Lifesciences Corporation's most recent stock split took place on June 1, 2020 with a 1:3 split ratio.

As of June 30, 2026, Edwards Lifesciences Corporation has an Altman Z-Score of 13.73, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.